Artificial intelligence is increasingly becoming a cornerstone in drug discovery, and VERAXA Biotech AG (NASDAQ: VRXA) is now looking to harness this power to advance its precision oncology pipeline. The company announced a collaboration with Ardigen, an AI-focused research organization, to combine computational biology and bioinformatics with VERAXA's proprietary BiTAC® platform. The goal is to leverage AI to identify the most effective dual-target combinations for T-cell engagers and antibody-drug conjugates (ADCs), while also improving target validation and reducing development risks.
VERAXA's innovative 'AND-gated' approach is particularly suited for AI-driven analysis. This method ensures that therapies are activated only when two cancer-associated targets are present on the same cell, which could increase specificity and reduce off-target effects. By integrating AI into the process, the companies hope to analyze complex genomic, proteomic, and clinical datasets more effectively, potentially uncovering new therapeutic opportunities that might otherwise go unnoticed.
The collaboration also opens the door to revisiting historical clinical and preclinical data. With AI's ability to process and reinterpret large volumes of information, researchers could identify safer applications for targets or therapies that were previously abandoned due to toxicity concerns. This could breathe new life into compounds that once showed promise but were shelved, offering a faster path to new treatments.
This strategic move comes at a time when the pharmaceutical industry is increasingly turning to AI to cut costs and accelerate development timelines. By reducing the risks associated with target selection and validation, VERAXA aims to streamline its pipeline and bring next-generation antibody-based therapeutics to patients more efficiently.
VERAXA's pipeline includes bispecific T-cell engagers and bispecific ADCs, among other innovative formats. The company's foundation is built on breakthroughs from the European Molecular Biology Laboratory, a prestigious institution known for pioneering life science research. With this new AI collaboration, VERAXA is positioning itself at the forefront of precision medicine.
For more details on this development, you can view the full article at https://ibn.fm/2U2hQ. Regular updates about VERAXA Biotech are available at www.VERAXA.com.
